AstraZeneca (GB:AZN) has released an update.
AstraZeneca has announced plans to invest $1.5 billion in a new manufacturing facility in Singapore dedicated to producing antibody drug conjugates (ADCs), a form of cancer treatment. Slated to be operational by 2029, this will be the company’s first facility capable of handling the full ADC manufacturing process. The investment reflects a commitment to sustainability, as the facility is designed for zero carbon emissions from day one.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
